Table 1. Individual clinical characteristics at inclusion and
allergy features at first and fourth oral food challenges of patients
under omalizumab and oral immunotherapy for cow’s milk allergy.
Figure 1. Study protocol illustration. After a period of
inclusion, corresponding to IgE-mediated diagnosis and prognosis
evaluation, omalizumab is administrated alone for 16 weeks. Oral
immunotherapy with fresh cow’s milk is then initiated by oral food
challenge (OFC1) in order to determine the first
cumulative dose (CTD1) and then the first threshold to
reach by up-dosing. OFCs were regularly performed to increase the
threshold. Study outcomes were assessed after OFC4.
Figure S1. Evolution of allergy features throughout protocol.Each dot and line correspond to one patient. OFC: oral food challenge.
Table S1. Responses to
satisfaction survey completed by children and their parents.